Brought to you by 
Cerulean closes $15mm Series D round; extension adds $13mm
03 Jan 2013
Executive Summary
Cerulean Pharma Inc. (nanopharmaceuticals for cancer) raised $15mm through its Series D round. New investor CVF LLC (affiliated with Henry Crown & Co.) participated and was joined by 18 other buyers, including returning backers Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital (which also takes a seat on the company's board), and Bessemer Venture Partners. Cerulean will use the proceeds to complete a Phase II trial of its CRLX101 for non-small cell lung cancer; support additional Phase II trials in other indications at academic medical centers; and advance a docetaxel nanodrug candidate into clinical trials.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cerulean closes $15mm Series D round; extension adds $13mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice